RSS

critical limb ischaemia (CLI)

The US Food and Drug Administration (FDA) has cleared the expanded access programme (EAP), submitted by Pluristem Therapeutics, for the use of PLX-PAD cell treatment in patients with critical limb ischaemia (CLI). more

News